RA

Rakesh Agarwal

Active Director Director DIN 07331527
DIN 07331527 First appointment Dec 2015 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2015
Shareholding value •••• Premium profile

About Rakesh Agarwal

Data last updated:

Rakesh Agarwal is a Director at Swisstar Medpharma Private Limited (since 2015). The company operates in Chemicals. Swisstar Medpharma Private Limited reported revenue of ₹1.90 Cr (FY 2017).

DIN 07331527
Primary Designation Director
Industry Chemicals
First Appointment 24 Dec 2015
Oldest Company Age 13 yrs
Largest company Swisstar Medpharma Private Limited · ₹1.90 Cr (FY 2017)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Swisstar Medpharma Private Limited U24232GJ2013PTC075610
Director24 Dec 20152013₹1.90 Cr (FY 2017)Active

Board colleagues of Rakesh Agarwal

Directorship timeline

Open interactive timeline →
Swisstar Medpharma Private Limited
Premium access

Shareholding and investment profile for Rakesh Agarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rakesh Agarwal

Rakesh Agarwal currently holds 1 directorship: Swisstar Medpharma Private Limited (Director, since 24 Dec 2015, revenue ₹1.90 Cr (FY 2017)).

Rakesh Agarwal was first appointed on 24 Dec 2015 as Director at Swisstar Medpharma Private Limited.

The current boards of Rakesh Agarwal's companies include Mohammedhusain Abdulgani Shaikh (Swisstar Medpharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available